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Abstract
Background: Azathioprine is used as an immunosuppressant in canine immune-mediated hemolytic anemia
(IMHA), but this potentially toxic and carcinogenic drug has not been proven to be beneficial. The aim of this
study was to determine the difference in outcome and survival of dogs with idiopathic IMHA treated with a
protocol that included azathioprine and prednisolone versus a protocol that included prednisolone alone.
Results: The study included 222 dogs with a hematocrit lower than 0.30 L/L and either a positive Coombs’ test or
spherocytosis and no evidence of diseases that could trigger IMHA. The clinical and laboratory data at the time of
diagnosis and the response to therapy and survival were compared in dogs treated according to the prednisolone
and azathioprine protocol (AP protocol; n = 149) and dogs treated according to the prednisolone protocol (P
protocol; n = 73). At study entry, the two groups were comparable, except that thrombocyte counts were
significantly lower and clinical signs had been present significantly longer in the AP protocol group. No significant
difference in survival was found between the two groups: the 1-year survival was 64% (95% CI 54 - 77%) in the P
protocol group and 69% (95% CI 59-80%) in the AP protocol group, respectively.
Conclusions: Azathioprine would appear not to be beneficial as standard treatment for all cases of IMHA; however,
a blinded, randomized clinical trial is needed to establish whether outcome is different with the two treatment
protocols.
Background
Glucocorticoids are the main component of the immu-
nosuppressive treatment of canine idiopathic immune-
mediated hemolytic anemia (IMHA), but cytotoxic
drugs such as azathioprine are advised for severe dis-
ease, such as cases with intravascular hemolysis or auto-
agglutination, and if the disease is refractory to
glucocorticoids alone [1-3]. A few studies have evaluated
the effect of azathioprine in canine IMHA and reported
conflicting results, ranging from a possible beneficial
effect to no effect [4-7]. Cytotoxic drugs can have
potentially severe side effects, such as bone marrow sup-
pression [8] and gastrointestinal disturbances, and long-
term adverse effects of cytotoxic drugs in humans and
animals include neoplasms, leukemia, and testicular and
ovarian dysfunction [9]. Similar problems have been
reported in people working with these agents [9].
Azathioprine is recognized by the International Agency
for Research on Cancer as being a possible or probable
cancer-causing agent [9].
We previously reported on the treatment of dogs with
idiopathic IMHA with an immunosuppressive protocol
consisting of azathioprine and prednisolone, at that time
the standard treatment in our clinic [10]. The lack of
evidence of a beneficial effect of azathioprine in canine
idiopathic IMHA combined with concerns about the
safety of the drug with regard to animal owners, animal
caretakers, and veterinarians prompted the question
whether the use of azathioprine is justified in dogs with
idiopathic IMHA. The standard treatment protocol was
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azathioprine and prednisolone to one including predni-
solone monotherapy. After several years, we now have
sufficient documented cases to compare the efficacy of
the two protocols. The aim of this study was to deter-
mine whether there are differences in the outcome and
survival of dogs with idiopathic IMHA treated according
to a protocol including azathioprine and prednisolone
(AP) versus a protocol including prednisolone alone (P).
Results
Clinical characteristics of dogs
Of 108 dogs eligible for the P protocol, 32 met exclusion
criteria and 3 further dogs were excluded because they
switched from the P protocol to the AP protocol, leav-
ing 73 dogs in the P protocol group. Of the 32 dogs
excluded, 6 had been treated with glucocorticoids for
more than 14 days, 5 had been diagnosed with babesio-
sis and/or ehrlichiosis (n = 2) or had visited an endemic
area (n = 3), 8 had concurrent inflammatory disease
(pneumonia n = 2, mesenteric lymphadenitis n = 1,
gastroenteritis n = 3, dermatitis n = 1, necrotizing inflam-
mation tail n = 1), 9 had neoplasia (carcinoma n = 3,
hematopoietic tumors n = 5, hemangiosarcoma n = 1), and
3 had a concurrent immune-mediated disease (hypothyr-
oidism n = 1, SLE n = 1, allergic dermatitis n = 1). The
owner of 1 dog decided not to start treatment.
Of 197 dogs eligible for the AP protocol, 48 met
exclusion criteria, leaving 149 dogs for inclusion in the
AP protocol group, as described earlier [10]. Of the 48
dogs excluded, 10 dogs had been diagnosed with babe-
siosis and/or ehrlichiosis (n = 3) or had visited an ende-
mic area (n = 7), 6 had concurrent lung disease, 4 had
neoplasia (spleen n = 2, mediastinum n = 1, heart n =
1), 17 had hematopoietic tumors (myeloid leukemia n =
2, malignant lymphoma n = 8, malignant histiocytosis n
= 5, hemangiosarcoma n = 2), 2 had SLE, and 1 had
renal disease. Three dogs were treated with medications
that can trigger IMHA, the owner of 1 dog chose not to
start treatment, and data were incomplete for 4 dogs.
To exclude concomitant disease, the 73 dogs in the P
protocol group underwent additional investigations,
namely, thoracic radiography (n = 33), abdominal ultra-
sound (n = 52), cytological investigations (spleen n = 22,
liver n = 31, lymph nodes n = 13, bone marrow n = 31,
skin nodules n = 4), pathological examination (liver n =
2, spleen n = 1, intestinal biopsies n = 2), gastroduode-
noscopy (n = 2), laparotomy (n = 1), electrocardiography
(n = 1), and bacteriological investigations (n = 2). For
the same reason, the 149 dogs included in the AP proto-
col group also underwent additional investigations,
namely, thoracic radiography (n = 19), abdominal ultra-
sound (n = 69), cytological examination (spleen n = 9,
l i v e rn=3 ,l y m p hn o d e sn=4 ,b o n em a r r o wn=1 7 ,
skin nodules n = 1), pathological examination (liver
n = 4, intestinal biopsies n = 2), gastroduodenoscopy
(n = 2) dogs, explorative laparotomy (n = 1), electrocar-
diography (n = 2). Cytology of the spleen showed that
the dogs in both groups had extramedullary erythropoi-
esis in the spleen and liver, and that most dogs had ster-
oid-induced hepatopathy. There was no evidence of
concomitant disease in any of the dogs.
The characteristics of the AP protocol group have
been described earlier [10]. Of the 73 dogs that were
included in the P protocol group, 12 dogs were cross-
breeds, 5 were Maltese terriers, 4 were Jack Russell ter-
riers, 4 were Labrador retrievers, 4 were Flat coated
retrievers, 3 were English Springer spaniels, 3 were
Dachshunds, 3 were Cairn terriers, 2 were Shetland
sheepdogs, and 2 were Appenzeller Sennen dogs, respec-
tively; the remaining 31 dogs were single dogs of other
breeds. Twenty-seven of the 73 dogs were males
(22 intact, 5 castrated) and 46 were females (24 intact,
22 castrated). In the AP protocol group, 61 were male
(46 intact, 15 castrated) and 88 were female (51 intact,
37 castrated). There was no significant difference in the
number of male and female dogs in the two groups (P =
0.77), or in the number of intact and neutered male and
female dogs (P = 0.67). Median body weight at the time
of diagnosis was 15.8 kg (range 2.5-45 kg) in the P pro-
tocol group and 18.7 kg (range 2.5-48.5 kg) in the AP
protocol group (P = 0.44).
The median age at diagnosis of IMHA was 4.6 years
(range 0.4 - 12.7 years) in the P protocol group and 5.7
years (range 0.3-13.9 years) in the AP protocol group;
this difference was not statistically significant (P = 0.09).
The median duration of clinical signs prior to diagnosis
of idiopathic IMHA was 3 days (range 0-141 days) in
the P protocol group and 6 (range 0-131 days) in the
AP protocol group; this difference was significantly sig-
nificant (P = 0.015). Anemia and clinical signs consistent
with a tentative diagnosis of IMHA were documented by
the referring veterinarian in 4 of 222 dogs 127, 128, 131,
and 141 days before the diagnosis of idiopathic IMHA
in our clinic.
There was no significant difference in the occurrence
of anorexia, vomiting, diarrhea, red urine, dyspnea,
fever, pale mucous membranes, icterus, or petechiae
between the treatment groups. Information from the
history and the physical examination, and the results of
laboratory investigations at the time of diagnosis of
I M H Aa r ep r e s e n t e di nT a b l e1 .T h r o m b o c y t ec o u n t s
were significantly lower in the AP protocol group than
in the P protocol group at the time of diagnosis (P =
0.00001), but none of the other laboratory variables
were significantly different at the time of diagnosis. The
laboratory procedures for determining PT, APTT, fibri-
nogen, and thrombocytes changed during the study, but
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and fibrinogen only. The mean PT before and after the
change was 7.9 (n = 111) and 7.4 (n = 21) seconds
(median 8 and 6.9 seconds), respectively, and the mean
fibrinogen concentration before and after the change
was 4.6 (n = 109) and 7.7 (n = 27) mg/L (median 4 and
7.5 mg/L), respectively. Only the PT and fibrinogen data
for P protocol patients that entered the study before the
change in laboratory procedures are included in Table 1
and were used in the univariate analysis. There were no
significant differences in PT and fibrinogen levels
between the two groups.
Therapy
Blood transfusions were given to 56 of 73 (76%) dogs in
the P protocol group (once in 45 dogs, twice in 10 dogs,
and three times in 1 dog) and in 98 of 149 (66%) dogs
in the AP protocol group (once in 78 dogs, twice in 18
dogs, three times in 1 dog, and four times in 1 dog).
The difference in transfusion requirement between the
two groups was not statistically significant (P = 0.61).
The median duration of prednisolone therapy was 68
days (range 0-936; n = 64) in the P protocol group and
59 days (range 0-622; n = 92) in the AP protocol group;
the difference in treatment duration was not statistically
significant (P = 0.20). In the AP protocol group, the
median duration of azathioprine therapy was 53 days
(range 0-622; n = 83).
Outcome
Dogs in the P protocol group made the first return visit
to the clinic after a median of 17 days (range 0-141; n =
43) and the second return visit after a median of 56
days (range 21-171; n = 25). Dogs in the AP protocol
group made the first return visit to the clinic after a
median of 25 days (range 2-83; n = 95) and the second
return visit after a median of 77 days (range 21-399; n =
69). The first and second return visits were significantly
earlier in the P protocol group than in the AP protocol
group (P = 0.001 and 0.0032, respectively, Table 2).
Apart from a significantly higher reticulocyte count in
the P protocol group at the first return visit (P = 0.027),
Table 1 Clinical signs and laboratory results for dogs in the AP protocol group and the P protocol group at time of
diagnosis
Azathioprine- Prednisolone Protocol Prednisolone Protocol
Clinical signs Present Absent n
a Present Absent nP
b
Anorexia 119 30 149 55 17 72 0.554
Vomiting 44 105 149 27 46 73 0.263
Diarrhea 23 126 149 17 56 73 0.153
Dyspnea 16 133 149 4 69 73 0.199
Fever 69 80 149 33 38 72 0.981
Pale mucous membranes 146 3 149 72 1 73 0.735
Icterus 57 92 149 27 46 73 0.855
Petechiae 8 141 149 1 72 73 0.156
Red urine 47 102 149 17 55 72 0.223
Laboratory results Median Range n Reference Median Range n
Hematocrit (%) 13 0.04-0.27 149 42-57 12 0.05-0.26 73 0.36
Reticulocytes (%) 8 0.1-90 147 < 2 5.8 0.1-51.5 64 0.29
Corrected reticulocytes (%) 2.7 0.01-19.2 147 < 2 2 0.02-14.3 64 0.11
Osmotic red cell fragility (mOsm/L) 238 120-317 139 < 162 250 131-317 28 0.28
Leukocytes (x10
9/L) 27.9 2.1-130 148 5.9-13.8 21.7 5.7-78.6 68 0.3
Band neutrophils (x10
9/L) 1.4 0-22.1 148 0-0.3 1 0-21.9 67 0.08
Urea (mmol/L) 7.6 2.9-69.5 123 3.0-12.5 7.4 2.3-49.5 45 0.8
Creatinine (μmol/L) 41.8 0.4-652 112 < 50 41.2 6.5-228.4 48 0.16
PT
c (seconds) 8 6-12 98 7 ± 1 7 7-10 13 0.74
APTT
d (seconds) 19.8 11-98 98 14 ± 1 17.4 9.1-64.8 37 0.98
Fibrinogen (g/L) 3.9 0.6-13.8 96 2-5 5 2.3-8.2 13 0.11
Thrombocytes (x10
9/L) 122 0-958 140 150-400 230 9-1079 65 0.00001*
Duration of clinical signs (days) 6 0-141 149 3 0-131 73 0.015*
a Number of dogs in which the parameter was determined.
b P = P value.
c PT = Prothrombin time.
d APTT = Activated partial thromboplastin time.
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thrombocytes, and red cell osmotic fragility between the
two groups at either visit (Table 2). Eight dogs in the P
protocol group relapsed after a median of 63 days
(range 7-581 days), as did 17 dogs in the AP protocol
group after a median of 112 days (range 32-1757 days).
There was no significant difference in the time to
relapse (P = 0.277) or in the number of relapses (P =
0.8939) between the two groups.
Analysis of survival
The 1-year survival was 64% (95% CI, 54-77%) in the P
protocol group and 69% (95% CI, 59-80%) in the AP
protocol group, respectively (Figure 1); this difference in
survival was not statistically significant (P = 0.65). The
difference in survival at 14 days, 6 months, and 1 year
was 1.7% (95% CI, minus 10 - 14%), 6.4% (95% CI,
minus 7.4 - 20%), and 6.4% (minus 11 - 19.9%), respec-
tively. At 1 year, 25 dogs had died of IMHA and 13
dogs were censored (1 had died of other causes, 9 were
alive with treatment, and 3 were alive without treat-
ment) in the P protocol group, and 36 dogs had died of
IMHA and 106 dogs were censored (3 had died of other
causes, 74 were alive with treatment, and 26 were alive
without treatment) in the AP protocol group. Survival
among dogs that lived longer than 14 days (n = 151)
Table 2 Results for laboratory tests and response categories for dogs with idiopathic IMHA treated according to the
AP protocol (n = 149) or the P protocol (n = 73) group at the time of the first and second return visits and relapse
Azathioprine-Prednisolone Protocol Prednisolone Protocol
First return visit Median Range n Reference Median Range nP
b
Hematocrit (%) 0.35 0.06-0.5 93 42-57 0.36 0.12-0.47 41 0.5
Thrombocytes (x10
9/L) 402 8-986 88 150-400 421 20-1555 29 0.48
Reticulocytes (%) 0.9 0.1-28 87 < 2 2 0.2-6.4 34 0.027*
Osmotic red cell fragility (mOsm/L) 176 136-258 82 < 162 164 125-247 24 0.06
Time after diagnosis
g (days) 25 2-83 95 17 0-141 43 0.001*
Response category
a No. dogs n No. dogs nP
b
No response
c 39 5 1 2 6
Improvement
d 87 95 25 26
Complete recovery
e 5 95 0 26 0.92
Second return visit Median Range n Reference Median Range nP
b
Hematocrit (%) 0.4 0.11-0.54 66 42-57 0.42 0.18-0.51 24 0.38
Thrombocytes (x10
9/L) 278 3-834 63 150-400 339 12-636 17 0.73
Reticulocytes (%) 0.8 0.1-12 60 < 2 1 0.3-9.7 18 0.39
Osmotic red cell fragility (mOsm/L) 163 133-238 58 < 162 165 142-206 11 0.40
Time after diagnosis
g (days) 77 21-399 69 56 21-171 25 0.0032*
Response category
a No. dogs n No. dogs nP
b
No response 0 62 0 13
Improvement 42 62 12 13
Complete recovery 20 62 1 13 0.12
Relapse
f Median Range n Reference Median Range np
b
Hematocrit (%) 0.28 0.06-0.44 17 42-57 0.31 0.10-0.41 5 0.96
Thrombocytes (x10
9/L) 132 0-382 15 150-400 327 228-426 2 0.15
Reticulocytes (%) 2.5 0.1-22 14 < 2 0.3 0.2-30.5 3 0.9
Osmotic red cell fragility (mOsm/L) 212 159-274 12 < 162 221 187-254 2 0.65
Time after diagnosis
g (days) 112 32-1757 21 63 7-581 8 0.27
aNumber of dogs counted in each response category.
b P = P value.
c No effect of therapy was defined as no increase in the hematocrit.
d Improvement was defined as an increase in hematocrit to < 0.36 L/L, or a hematocrit >0.36 L/L but with a positive Coombs’ test or an increased osmotic red
cell fragility.
e Complete recovery was defined as an increase in the hematocrit to >0.36 L/L, a negative Coombs’ test, and an osmotic red cell fragility within the reference
range.
f Relapse was defined as a decrease in the hematocrit after an initial improvement or complete recovery in combination with the recurrence of a positive
Coombs’ test or increased red cell fragility.
g The times of the first and second return visits or when a relapse occurred were retrieved from the medical record.
Piek et al. BMC Veterinary Research 2011, 7:15
http://www.biomedcentral.com/1746-6148/7/15
Page 4 of 9was not significantly different between the two groups
(P = 0.649)(Table 3).
The proportional hazards assumption was valid for all
variables that were significant in univariate and multi-
variate analyses. Results of the univariate analysis of the
pooled data from the two groups with P < 0.20 and the
variable treatment (P = 0.65) are presented in Table 4.
The best multivariate model included plasma urea con-
centration (HR = 2.56; 95% CI, 1.729-3.789; n = 164)
and icterus (HR = 2.94; 95% CI, 1.60-5.42; n = 164) as
positive predictors of death, and spherocytes (HR =
0.38; 95% CI, 0.2-0.72; n = 164) as a negative predictor
of death. The HRs were calculated for clinically relevant
intervals.
Discussion
The aim of this study was to determine whether treat-
ment according to a protocol including azathioprine and
prednisolone (AP) compared with a protocol including
prednisolone (P) alone leads to differences in outcome
and survival in dogs with idiopathic IMHA. There were
no significant differences between the treatment groups
in the duration of immunosuppressive therapy, number
of blood transfusions, survival (Figure 1), or treatment
response.
Thrombocyte counts at the time of diagnosis were sig-
nificantly lower in the AP protocol group than in the P
protocol group. Although a low thrombocyte count has
a negative influence, mainly on short-term survival
[10,11], it is unlikely that the lower thrombocyte count
in the AP protocol group masked a potential beneficial
effect of azathioprine for a number of reasons. Firstly,
the most likely explanation for the low thrombocyte
count in dogs with IMHA is the decrease over time due
to both immune-mediated destruction and thrombotic
tendencies [11-14]. The median duration of clinical
signs prior to diagnosis ofi d i o p a t h i cI M H Aw a st h e
longest in the AP protocol group, which might explain
the lower thrombocyte count in this group. Studies of
IMHA show survival curves with similar slopes, with
most deaths occurring in the first 2 weeks after diagno-
sis, despite differences in severity of clinical disease
[4,5,15]. This suggests that recovery from the acute
IMHA crisis and the associated pathology, such as
thrombosis and disseminated intravascular coagulation,
takes about 2 weeks. Indeed, at the first return visit
Figure 1 Kaplan-Meier survival curve for dogs with idiopathic
IMHA treated according to the AP protocol (n = 149) or the
P protocol (n = 73).
Table 3 Life table and estimated survival results for the AP protocol group (n = 149) and P protocol group (n = 73)
at 14 days, 6 months, and 1 year after the date of diagnosis of idiopathic IMHA and at the time of the scheduled first
visit (28 days) and second control visit (70 days)
Azathioprine-Prednisolone Protocol







Estimated survival 95% CI
Interval
14 98 30 21 0.785 0.719 - 0.856
28 61 31 57 0.776 0.710 - 0.849
70 67 32 50 0.756 0.686 - 0.833
182 31 35 86 0.725 0.647 - 0.812
365 12 36 106 0.685 0.588 - 0.802
Prednisolone Protocol
14 56 17 0 0.767 0.676 - 0.870
28 53 19 1 0.738 0.644 - 0.847
70 46 21 8 0.709 0.611 - 0.822
182 42 24 11 0.661 0.559 - 0.782
365 36 26 18 0.643 0.539 - 0.767
a Number of dogs alive.
b Cumulative number of dogs in each protocol group that died of idiopathic IMHA.
c Cumulative number of dogs in each protocol group that were censored.
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t h et w og r o u p s( T a b l e1 ) .W eh a v ep r e v i o u s l yf o u n d
that thrombocytopenia at the start of therapy decreases
short-term survival but not long-term survival [10]. On
the basis of this, it is unlikely that the difference in
thrombocyte count at the time of diagnosis had an effect
on long-term outcome. Secondly, it is debatable whether
azathioprine has a clinical effect within 2 weeks of ther-
apy initiation in dogs. Although azathioprine decreased
the lymphocyte blastogenic response in dogs after
7 days of treatment [16], it induced significant changes
in immunoglobulin levels and lymphocyte numbers only
after 2 weeks of treatment [17]. Thirdly, the best multi-
variate Cox proportional hazards model (Table 3)
contained urea plasma concentration, icterus, and spher-
ocytes as significant predictors of death due to IMHA.
Neither inclusion of the variable “treatment protocol”
nor “thrombocytes” improved this model significantly.
F o rt h e s er e a s o n s ,w ec o n c l u d et h a tt h ed i f f e r e n c ei n
thrombocyte count between the two protocol groups at
the start of the study is not likely to have had an influ-
ence on long-term survival.
One of the drawbacks of using historical controls is
that time-related differences in the study population or
in the treatment received, other than the effect of
azathioprine, might confound the effect of treatment.
Because inclusion criteria were unchanged throughout
the trial and based on the results of objective quantita-
tive laboratory tests, it is unlikely that this led to unrec-
ognized inclusion bias. To minimize exclusion bias
based on time-related differences in the diagnostic
work-up, at the time of the study each individual case
was evaluated by one of the authors to ensure that
causes of secondary IMHA had been appropriately
excluded. Although the addition of azathioprine was the
only identifiable difference in treatment between the
t w og r o u p s ,i tc a n n o tb ee x c l u d e dt h a ts u p p o r t i v ec a r e
in the intensive care unit had improved during the trial.
In our institute, contrary to what is advocated by others
[7], it is not routine practice to use antithrombotics or
anticoagulants that might otherwise have influenced
outcome.
Although there were no treatment-related differences
in treatment response and survival, there were some dif-
f e r e n c e sb e t w e e nt h el a b o r a t o r yr e s u l t sa tt h et i m eo f
first and second return visit. The reticulocyte count in
the P protocol group was significantly higher, which,
although modest, might indicate that the red cell regen-
eration response was still active, because the first return
visit in the P protocol group was 6 days earlier than that
of the AP protocol group. Alternatively, it might reflect
azathioprine-induced bone marrow suppression in the
AP protocol group [8]. Azathioprine related side effects
were noted in 12 of 149 (8.1%) dogs in the AP protocol
group [10]. This seems a less likely explanation, how-
ever, since hematocrit, leukocyte, and thrombocyte
counts at the time of first return visit were not signifi-
cantly different between the two treatment groups. Eigh-
teen dogs in our study developed idiopathic IMHA
before the 1 year of age, in contrast with previous
reports describing an onset only after the first year of
age [3-5,15,18]. The clinical and laboratory findings and
survival of these 18 dogs were not significantly different
from those of the other 204 dogs in this study (data not
shown).
Azathioprine is listed as a human carcinogen [9], and
for this reason its use should be restricted in veterinary
medicine to indications for which an evidence-based
effect has been demonstrated, or to studies seeking to
prove its beneficial effect [9]. While there was no signifi-
cant difference in 1-year survival between the two
groups, the confidence interval included both a 20%
superior survival and a 11% lower survival. Given the
limitations that are inherent to a retrospective study,
this potential difference in outcome might be regarded
Table 4 Univariate and multivariate Cox proportional
hazards results for risk of death in 222 dogs with
idiopathic IMHA for variables determined at time of first




a Hazard ratio N
b 95% CI P
c
Icterus 2.47 222 1.52 - 4 0.0003*
Urea (20 mmol/L) 2.22 168 1.55-3.19 0.0004*
Creatinine
d (50 μmol/L) 1.28 160 1.15-1.42 0.0012*
Red cell osmotic fragility 0.426 181 0.221 - 0.819 0.018*
Thrombocytes (50 ×10
9/L) 0.902 205 0.821-0.991 0.0184*
Age (years) 1.09 221 1.01-1.17 0.0266*
APTT
e (seconds) 1.03 135 1-1.05 0.0445*
Spherocytes 0.663 215 0.396 - 1.11 0.115
Hematocrit (L/L) 0.0173 222 0.00011 - 2.77 0.109
Treatment protocol 1.12 222 0.679-1.86 0.65
Multivariate analysis
Urea (20 mmol/L) 2.56 164 1.729-3.789 0.0001*
Icterus 2.94 164 1.60 - 5.42 0.0005*
Spherocytes 0.38 164 0.2 - 0.72 0.0023*
a Variables were entered in the Cox proportional hazards model either as a
factor or as a continuous variable, in which case the hazard ratio was
calculated for the interval that is given in the table.
b Number of dogs is given in which the parameter was determined for which
the Cox proportional hazards model calculated the hazard ratio.
c P = P value
d Plasma creatinine concentrations were corrected for body weight (van den
Brom and Biewenga, 1981).
e APPT = Activated partial thromboplastin time
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trolled study is necessary to estimate the true effect size
of the AP protocol for the treatment of canine IMHA.
The estimated effect size in this study can be used for
sample size calculations [19]. However, given the side
effects in dogs and the carcinogenicity in humans, we
feel that the findings of this study do not justify the use
of azathioprine in each IMHA patient. Given that at
least 95% of the dogs in both protocol groups were clas-
sified as improved or completely recovered at the first
control visit a median of 25 days after the start of ther-
apy (Table 2), we suggest that the addition of azathiopr-
ine to the prednisolone protocol should be considered if
there is no, or an inadequate, response to prednisolone
after 2-3 weeks of treatment, provided the guidelines for
adjustment of the prednisolone treatment have been
followed.
Conclusions
The absence of a statistically significant difference in
survival indicates that there may be no beneficial effect
of including azathioprine in the standard treatment of
all cases of IMHA; however a blinded, randomized clini-
cal trial is needed to establish the true difference in
effect between the two treatment protocols.
Methods
Patients
The dogs had been referred to the Utrecht University
Clinic of Companion Animals (UUCCA) from 1st Janu-
ary 1994 to 31st December 2005. Inclusion criteria were
a hematocrit < 0.30 L/L and either a positive Coombs’
test or the presence of spherocytes in a blood smear. All
dogs had been treated according to either a standard
immunosuppressive protocol consisting of azathioprine
and prednisolone (1st January 1994 until 31st December
2000) or a protocol consisting of prednisolone alone
(1st January 2002 until 31st December 2005). A com-
plete medical record had to be present.
Dogs were excluded if they had evidence of diseases
that could induce IMHA, such as neoplasia, medica-
tions, and infectious diseases. As a result, dogs that had
visited areas where ehrlichiosis and babesiosis are ende-
mic within 3 weeks of the diagnosis of idiopathic IMHA
were excluded unless serologic examination for Ehrli-
chia canis and Babesia canis or B. gibsonii was negative.
Dogs that had received immunosuppressive treatment
for longer than 14 days before referral to the UUCCA
were excluded. Dogs that were referred between 31st
December 2000 and 1st January 2002 were excluded to
avoid possible selection bias, since in that period both
treatment protocols were used.
Breed, sex, complete history, and physical examination
were recorded, including age at time of first diagnosis of
idiopathic IMHA, anorexia, vomiting, diarrhea and dark
red urine, as well as the presence of an increased rectal
temperature, pale mucous membranes, icterus, and pete-
chiae. Additional diagnostics were performed if judged
necessary by the attending clinician.
Laboratory tests
All tests at the time of diagnosis were performed at the
UUCCA. The outcomes of the following laboratory tests
performed on admission were retrieved from the medi-
cal records: complete blood count (CBC), reticulocyte
count, presence of spherocytes (confirmed by one of the
authors, CP), Coombs’ test, osmotic red cell fragility,
plasma urea and creatinine concentrations. Data that
were available for a subset of the patients only were not
recorded. During return visits, approximately 4 and
10 weeks after start of treatment, CBC, reticulocyte
count, Coombs’ test and osmotic red cell fragility were
determined. A monovalent direct Coombs’ antiglobulin
test was performed using anti-dog IgG (Central Blood
Laboratory, Nordic), anti-dog IgM antibodies (Nordic)
and, before January 2005, an anti-dog complement anti-
body (Nordic), for agglutination of the patients’ red
cells; results were reported as negative, weakly positive,
or positive. The osmotic fragility of erythrocytes was
determined as previously described [20]. Plasma creati-
nine concentrations were corrected for body weight [21].
The prothrombin time (PT), activated partial throm-
boplastin time (APTT), and fibrinogen concentration
were recorded when measured (Option 4, BioMerieux).
PT and APTT were considered prolonged if they were
increased at least 10% above levels measured in normal
pooled canine citrated plasma. From March 2003
onward, coagulation profiles were determined with the
Thrombolyser Compact-X (Trinity Biotech PLC) and
new reference values were established for this system.
From March 2003 onward, the hematology analyzer was
changed from the combination of the ABX Helios and
ABX Helios 5 Diff (ABX International) to the ADVIA
120 (Siemens Medical Solutions Diagnostics) and refer-
ence values were established for this system.
Therapy
Blood transfusions, alone or in combination with IV
fluid therapy, were given if considered necessary by the
attending clinician. A transfusion consisted of the
equivalent of 450 mL of donor blood. In dogs weighing
less than 10 kg, a lower transfusion volume was given,
with a maximum of 40 mL/kg. Depending on availabil-
ity, either packed red blood cells or fresh whole blood
was used. The number of blood transfusions was noted.
All clinic-owned donor dogs used in the study were
DEA 1.1 and 1.2 negative. No cross-match was per-
formed in the case of first blood transfusion. Only in
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transfusion was given, were cross matches performed.
Two treatment protocols were used. A standard proto-
col consisting of a combination of prednisolone and
azathioprine (AP protocol) was instituted in dogs that
were treated before 31st December 2000. From 1st Janu-
ary 2002 onward, the standard protocol for dogs with
idiopathic IMHA contained prednisolone only (P proto-
col). In both protocols prednisolone was given following
the same schedule. The response category (see below)
was assessed at least once daily during hospitalization
and during return visits that were scheduled 4 and 10
weeks after the start of therapy. As long as the response
category was no change, prednisolone (Alfasan) was
given in a dosage of 2 mg/kg/day PO. Dogs that were
not able to take oral medication were hospitalized and
treated with dexamethasone (0.5-1 mg/kg/day) IV or
SC. Once the response had improved, prednisolone
therapy was started at a dosage of 2 mg/kg/day PO for
3 days, followed by 1.5 mg/kg/day PO for 7 days, 1 mg/
kg/day PO for 10 days, 0.5 mg/kg/day PO for 14 days,
after which the same dose was given on alternate days
for 14 days and subsequently tapered down to 0.25 mg/
kg/day PO for 21 days. If the outcome was assessed as
complete recovery at the 4- or 10-week return visit, the
prednisolone therapy protocol described above was fol-
lowed. If relapse occurred at any time during this treat-
ment, the prednisolone therapy protocol was started
f r o mt h eb e g i n n i n g .I fa tt h e4o r1 0w e e kr e t u r nv i s i t
the treatment response was assessed as improved but
there was no complete recovery, the duration of the
intervals during which prednisolone was tapered, as
described above, was doubled. Additionally, in the AP
protocol, dogs were treated with azathioprine (Imuran,
Glaxo-Wellcome) at a dosage of 2 mg/kg/day PO for
dogs weighing < 20 kg. The daily azathioprine dose in
dogs of 25, 30, 40 and 50 kg was maximized at 45, 50,
60 and 70 mg, respectively. Azathioprine treatment was
stopped 10 days after prednisolone treatment.
Outcome
The response to therapy was retrieved from the medical
record. The response was assessed at the actual time of
the first and second return visits. At both times the
findings were compared to those of the last visit. We
defined four response categories. Complete recovery
was defined as an increase in the hematocrit to >0.36
L/L, a negative Coombs’ test, and an osmotic red cell
fragility within the reference range. Improvement was
defined as a modest increase in the hematocrit or an
increase to >0.36 L/L but with a positive Coombs’ test
or an increased osmotic red cell fragility. No response
was defined as no increase in the hematocrit. And
relapse was defined as a decrease in the hematocrit
after an initial improvement or complete recovery
in combination with the recurrence of a positive
Coombs’ test or increased red cell fragility. The time at
which a relapse occurred was retrieved from the medi-
cal record.
Survival was determined by telephone contact with the
owner by one of the investigators (GJ for the AP proto-
col group and ES for the P protocol group). If we were
unsuccessful in contacting the owner, the last date of
contact was recorded from the file. The outcome at the
last date of contact was divided into three categories:
death due to IMHA, death due to another cause, and
alive with or without treatment.
Statistical analysis
Statistical analysis of the data was performed using
S-plus statistical package (Insightful Corporation). Com-
parisons between the two protocol groups were made
assuming no difference between the treatment groups.
Non-parametric tests were used when the data were not
normally distributed (Chi-square or Fisher’s exact test
for categorical variables and Two-sample Wilcoxon
rank-sum test for continuous variables).
As described above, minor changes were made in the
laboratory procedures for PT, APTT, fibrinogen, and
thrombocytes during the peri o dt h a td o g sw e r ee n t e r e d
in the P protocol group. The results for these variables
in the P protocol group were split into two groups,
before and after the change, and handled as individual
groups during the statistical analysis. Comparisons
between the AP protocol group and both subgroups of
the P protocol groups were made using the Kruskall-
Wallis c
2 test. In case of multiple testing, Bonferroni
correction was performed.
Survival analysis was performed for the AP protocol
group and the P protocol group. The end point was
death due to IMHA. Dogs that were alive at the end of
the study or had died of other causes were censored.
Survival curves were drawn with the Kaplan Meier
method.
The treatment protocol used and the variables
recorded at the date of first diagnosis, with the excep-
t i o no ft h ev a r i a b l eb r e e d ,w e r ee v a l u a t e di nau n i v a r i -
ate Cox proportional hazard model and used to
generate hazard ratios (HRs). The variable treatment
protocol and the variables significant at the P < 0.20
level in the univariate analysis were introduced in a
multivariate model, allowing for interaction between
variables. Multivariate analysis was performed by for-
ward stepwise selection using a probability of P < 0.05
in the likelihood ratio test as a criterion for inclusion.
Compliance with the proportional hazards assumption
was tested graphically by plotting the Schoenfeld resi-
duals against time.
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